All News

Found 118 articles

• 

  Clinical Catch-Up: October 12-16

  10/19/2020

  It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
• 

  Cyclerion Presents Bad News in Sickle Cell Study, Good News in CNS Trial

  10/15/2020

  Cyclerion is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases affecting the central nervous system (CNS).

• Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell DiseaseStudy results do not support further internal development

  10/14/2020

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease.

• Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects

  10/14/2020

  Showedsignificant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

• GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference

  9/9/2020

  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 15.

• Cyclerion to Participate at Upcoming September 2020 Investor Conferences

  9/4/2020

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase stimulators for the treatment of serious and orphan diseases, announced that Company management will be participating in several upcoming September 2020 investor conferences

• Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program

  8/25/2020

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, announced that it has been awarded a grant from the Alzheimer's Association’s Part the Cloud-Gates Partnership Grant Program.

• Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million

  8/6/2020

  – Grew LINZESS ® (Iinaclotide) total prescription demand by 9% year-over-year; new-to-brand prescription demand grew >15% in June 2020 compared to March 2020 – – Made important updates designed to strengthen IW-3718 Phase III program; FDA indicated that long-term safety study for IW-3718 is not required for an NDA submission – – Reinstating full year 2020 total revenue and LINZESS net sales growth guidance; reiterating adjusted EBITDA gu

• Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

  8/3/2020

  -   IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   - -  Completed $24 million equity private placement to accelerate clinical development of IW-6463 for the CNS diseases MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) and ADv (Alzheimer's Disease with Vascular pathology) and of olinciguat for sickle cell disease   - -  CNS focused webcast event held to highlight IW-6463 develop

• Cyclerion Therapeutics Completes $24 Million Private Placement

  7/30/2020

  -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  - - IW-6463 translational pharmacology and olinciguat STRONG Phase 2 top line clinical study results remain on track for late summer and late Q3 2020, respectively  -

• Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit

  7/17/2020

  Cyclerion Therapeutics, Inc. announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on “Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies” at the Annual Biomarkers in Alzheimer’s Disease Summit that was held virtually on July 15, 2020.

• Cyclerion to Host Webcast Investor Event on July 9, 2020

  6/18/2020

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that it will host a webcast investor event on July 9, 2020 from 8:15 a.m. to 9:30 a.m. Eastern Time.

• 

  Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess

  5/29/2020

  Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.

• Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic

  5/6/2020

  Increased total revenue by 16% year-over-year to $80 million, driven primarily by U.S. LINZESS collaboration revenue of $71 million

• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Cyclerion Updates Corporate Progress

  4/10/2020

  – Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –       –  Closed enrollment for IW-6463 translational pharmacology clinical study ; topline data readout expected mid-year 2020 – – Company continues discussions to out-license praliciguat – CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development o

• 

  BioSpace Movers & Shakers, Feb. 21

  2/21/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

• Kallyope Inc. Appoints Peter Hecht to Board of Directors

  2/20/2020

  NEW YORK , Feb. 20, 2020 /PRNewswire/ -- Kallyope Inc ., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced that Peter Hecht , Ph.D., CEO of Cyclerion Therapeutics, has been appointed to the company's Board of Directors. Prior to joining Cyclerio

• Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

  2/13/2020

  Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance.

• Science Exchange Adds Cyclerion President & CSO, Mark Currie, to its Board of Directors

  2/12/2020

  Science Exchange, the world’s leading SaaS-enabled marketplace for outsourced research and development (R&D), announced today that Mark Currie, Ph.D., President and Chief Scientific Officer of Cyclerion, has joined the Science Exchange Board of Directors